NEWSWIRETODAY Press Release & Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: Daneen Therapeutics, Inc.

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Charles W. Stiefel Appointed to M.D. Anderson Cancer Center Board of Visitors - Pharmaceutical Executive Charles W. Stiefel has been appointed to the M.D. Anderson Cancer Center's Board of Visitors - DaneenTherapeutics.com
Charles W. Stiefel Appointed to M.D. Anderson Cancer Center Board of Visitors

 

NewswireTODAY - /newswire/ - Houston, TX, United States, 2012/12/10 - Pharmaceutical Executive Charles W. Stiefel has been appointed to the M.D. Anderson Cancer Center's Board of Visitors - DaneenTherapeutics.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The MD Anderson Cancer Center Board of Visitors (BOV), an appointive board of volunteers dedicated to advancing the initiatives of The University of Texas

MD Anderson Cancer Center, welcomes philanthropist Charles W. Stiefel of Raleigh, North Carolina as a new member. Stiefel, along with his wife Daneen, previously made a one million dollar gift to M.D. Anderson to endow a professor's Chair in the Head & Neck Center. The Stiefel endowment was made in honor of the 3 physicians who successfully treated Stiefel for 2 types of cancer in 2007.

"I am deeply honored to join this prestigious Board of Visitors and to help M.D. Anderson succeed in its mission of Making Cancer History®,” said Stiefel. "Cancer claimed the lives of my mother, father, younger brother and uncle - - as well as several of my friends - - and there is probably no one in America who has not lost a friend or loved one to this terrible disease. That is why my primary philanthropic focus is to fund cancer research and endeavor to help physicians improve patient outcomes."

Since the board’s inception in 1957, BOV members have played a significant role in MD Anderson’s mission to eradicate cancer by helping raise funds, awareness and support for the institution.

“We’re grateful to these business and community leaders from across the nation for not only their efforts to secure philanthropic contributions to the institution, but also for their personal gifts of time, resources and talents,” said Ronald DePinho, M.D., president of MD Anderson. “Their generosity is crucial in advancing the institution’s cancer research and patient care initiatives. Certainly the BOV’s support will have a significant role in achieving our goals to drastically reduce cancer mortality through the recently announced Moon Shots Program.”

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Daneen Therapeutics, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Charles W. Stiefel Appointed to M.D. Anderson Cancer Center Board of Visitors

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Press Office - DaneenTherapeutics.com 
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Daneen Therapeutics, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Daneen Therapeutics, Inc. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ono Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera
JFCR, NEC, and Taiho to Develop Cancer Vaccines Utilizing Whole-Genome Information
Ono Receives Supplemental Approval of Combination Therapy with BRAFTOVI® Capsule, a BRAF Inhibitor, for the Indication of Colorectal Cancer
WuXi AppTec Receives Frost & Sullivan’s 2025 Global Company of the Year Recognition in the CRDMO Industry
Frost Radar™ Identifies Top Growth and Innovation Leaders in Pharmaceutical and Biotech Laboratory Information Management Systems
Ono Submits an Application for Approval of Cenobamate (ONO-2017), Antiseizure Medications in Japan
Viva Biotech Receives Frost & Sullivan’s 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry
Biotech Firm 4Dcell Selected to Showcase Next-Gen Cardiac Drug Testing Platform At EIC Corporate Day
Deciphera Receives European Commission Approval of ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
Ono and Bristol-Myers Squibb KK Receive Supplemental Approval of Opdivo and Yervoy in Combination Therapy in Japan
Ono Enters into A Definitive Agreement with Seikagaku for Co-development and Marketing Collaboration on Gel-One for the Treatment of Osteoarthritis
Deciphera Announces Positive CHMP Opinion for ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
Novotech Earns Frost & Sullivan’s 2025 Global Company of the Year Recognition for Excellence in Biotech Clinical Research Services
Ono Pharmaceutical and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
NEC and Chugai Pharmaceutical Use AI to Potentially Enhance Cancer Treatment

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2005-2025 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)